Cresanto Global

Raymed Labs Limited operates in the pharmaceutical sector, with a business structure covering manufacturing, production, trading, and distribution of various products. The company is committed to practicing good corporate governance across all its activities, striving to operate in a fair, judicious, and transparent manner. Its main goal is to create an environment of fairness and transparency, which helps in securing long-term shareholder value while respecting the rights of every stakeholder. The company’s diverse business activities include dealing in pharmaceuticals, medicals, chemicals, and both veterinary and human medicines. To support its long-term strategic plans, the company aims to achieve greater financial flexibility and create an optimal financing structure for future initiatives. During the fiscal year 2023-24, it demonstrated improved financial performance by successfully reducing its net loss compared to the previous year.;